Cure8 research brief
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for symptom control and mucosal healing.
Adults with moderate-to-severe ulcerative colitis, clinicians who treat IBD, and researchers studying biologic therapies or immune pathways in IBD.
The article is a narrative literature review of phase II/III trials, extension studies, observational cohorts, and meta-analyses focusing on IL-23 blockade in ulcerative colitis. It highlights mirikizumab as having the strongest long-term evidence among the three drugs discussed.
The review notes improvements in clinical remission, endoscopic healing, histologic outcomes, and quality of life, and describes low rates of serious adverse events and treatment discontinuation in the included studies.
The review also states that more real-world data and head-to-head comparisons are needed to define optimal placement of IL-23 inhibitors among other biologics and oral therapies. This appears grounded in the article abstract and declared methodology (PubMed and ClinicalTrials.gov search) rather than new trial results presented here.
The article is a narrative literature review (PubMed and ClinicalTrials.gov sources) and the extraction is based on the article abstract. The review calls for additional real-world evidence and head-to-head trials to better define comparative effectiveness and long-term safety.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
